智通财经APP讯，山东新华制药股份(00719)发布公告，近日，公司收到国家药品监督管理局核准签发的阿司匹林肠溶片(100mg)的《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。
阿司匹林肠溶片为血液系统用药，临床上主要用于不稳定性心绞痛(标准治疗的一部分);急性心肌梗死(标准治疗的一部分);预防心肌梗死复发;动脉血管手术或介入手术后，如主动脉冠状动脉静脉搭桥术、经皮冠状动脉腔内血管成形术;预防短暂性脑缺血发作(TIA)和已出现早期症状后预防脑梗死。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.